Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
NCT03611738Phase 1Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2019
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ceritinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Maximum Tolerated Dose at 6 months and Overall Response at 30 months. Started Feb 2019; status: active, not recruiting.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03611738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03611738.